The <scp>Heart Failure Association Atlas</scp>: <scp>Hanagement Statistics</scp> 2019

European Journal of Heart Failure 23, 906-914 DOI: 10.1002/ejhf.2143

Citation Report

#	Article	IF	CITATIONS
1	Making heart failure count. European Journal of Heart Failure, 2021, 23, 917-918.	7.1	3
2	The war on heart failure. European Journal of Heart Failure, 2021, 23, 915-916.	7.1	2
3	Pharmacological Management of Heart Failure: A Century of Expert Opinions in Cecil Textbook of Medicine. American Journal of Therapeutics, 2021, 28, e292-e298.	0.9	4
4	Elevated asleep blood pressure and non-dipper 24h patterning best predict risk for heart failure that can be averted by bedtime hypertension chronotherapy: A review of the published literature. Chronobiology International, 2023, 40, 63-82.	2.0	4
5	June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment. European Journal of Heart Failure, 2021, 23, 847-849.	7.1	0
6	The â€~Peptide for Life' Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across <scp>Europe</scp> . European Journal of Heart Failure, 2021, 23, 1432-1436.	7.1	10
7	Best of European Journal of Heart Failure at the <scp>ESC</scp> / <scp>HFA</scp> Heart Failure Congress 2021. European Journal of Heart Failure, 2021, 23, 1424-1427.	7.1	1
8	Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. Revista Portuguesa De Cardiologia, 2021, 40, 975-983.	0.5	6
9	Mechanism of miR-30b-5p-Loaded PEG-PLGA Nanoparticles for Targeted Treatment of Heart Failure. Frontiers in Pharmacology, 2021, 12, 745429.	3.5	7
10	Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry. International Journal of Cardiology, 2021, 343, 63-72.	1.7	23
11	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the <scp>S</scp> wedish <scp>H</scp> eart <scp>F</scp> ailure <scp>R</scp> egistry. European Journal of Heart Failure, 2021, 23, 1844-1854.	7.1	42
12	HeartMan DSS: A decision support system for self-management of congestive heart failure. Expert Systems With Applications, 2021, 186, 115688.	7.6	9
13	ICD-10 code-based definition of heart failure in Saint Petersburg electronic health records: prevalence, health care utilization and outcomes. Russian Journal of Cardiology, 2021, 26, 4621.	1.4	4
14	ESC/HFA Quality of Care Centres: the ultimate frontier in unifying heart failure management. European Heart Journal, 2021, 43, 11-13.	2.2	5
15	Navigating between Scylla and Charybdis: challenges and strategies for implementing guidelineâ€directed medical therapy in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 1999-2007.	7.1	22
16	The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. European Heart Journal, 2022, 43, 367-376.	2.2	13
17	Impact of age, gender and heart failure on mortality trends after acute myocardial infarction in Italy. International Journal of Cardiology, 2022, 348, 147-151.	1.7	9
18	Education and certification on heart failure of the <scp>H</scp> eart <scp>F</scp> ailure <scp>A</scp> ssociation of the <scp>E</scp> uropean <scp>S</scp> ociety of <scp>C</scp> ardiology. European Journal of Heart Failure, 2022, 24, 249-253.	7.1	6

TITATION REDORT

#	ARTICLE	IF	CITATIONS
19	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure Failure, 2022, 24, 132-142.	7.1	30
20	Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research, 2023, 118, 3272-3287.	3.8	517
21	The growing importance of heart failure in myocardial infarction. International Journal of Cardiology, 2022, 352, 100-101.	1.7	2
22	Roadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: how to implement excellence in clinical practice. Journal of Cardiovascular Medicine, 2022, 23, 149-156.	1.5	23
23	Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). European Heart Journal, 2022, 43, 2185-2195.	2.2	12
24	Immune response in heart transplantation: a bibliometric analysis. Journal of Thoracic Disease, 2022, 14, 635-645.	1.4	1
25	Epigenetic remodeling in heart failure with preserved ejection fraction. Current Opinion in Cardiology, 2022, 37, 219-226.	1.8	7
27	Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 2224-2234.	2.2	22
28	A year in heart failure: an update of recent findings. ESC Heart Failure, 2021, 8, 4370-4393.	3.1	28
29	Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 975-983.	0.2	0
30	Prevalence and characteristics of patients with heart failure needing palliative care. BMC Palliative Care, 2021, 20, 184.	1.8	4
31	Figures of the Heart Failure Association: Doctor Amina Rakisheva, Board Member, 2020–2022. European Journal of Heart Failure, 2022, 24, 741-742.	7.1	0
32	The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Cardiologia Croatica, 2022, 17, 27-43.	0.0	1
33	Periodontitis Is Associated With Heart Failure: A Population-Based Study (NHANES III). Frontiers in Physiology, 2022, 13, 854606.	2.8	10
34	Heart failure in the general population and impact of the 2021 European Society of Cardiology Heart Failure Guidelines. ESC Heart Failure, 2022, 9, 2157-2169.	3.1	10
35	An update on global epidemiology in heart failure. European Heart Journal, 2022, 43, 3005-3007.	2.2	26
36	Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly. Cardiac Failure Review, 0, 8, .	3.0	1
37	20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. Journal of Cardiovascular Development and Disease, 2022, 9, 149.	1.6	7

#	Article	IF	CITATIONS
38	Structured, Harmonized, and Interoperable Integration of Clinical Routine Data to Compute Heart Failure Risk Scores. Life, 2022, 12, 749.	2.4	0
39	Role of depressive symptoms in the prognosis of heart failure and its potential clinical predictors. ESC Heart Failure, 2022, 9, 2676-2685.	3.1	10
40	Recurrent heart failure hospitalizations increase the risk of mortality in heart failure patients with atrial fibrillation and type 2 diabetes mellitus in the United Kingdom: a retrospective analysis of Clinical Practice Research Datalink database. BMC Cardiovascular Disorders, 2022, 22, .	1.7	0
41	Left ventricular ejection fraction as the primary heart failure phenotyping parameter. European Journal of Heart Failure, 2022, 24, 1158-1161.	7.1	15
42	Centres of excellence in heart failure: results of an accreditation programme in Spain (2017–2021). ESC Heart Failure, 2022, 9, 3649-3654.	3.1	5
43	Exercise Training Effects on Circulating Endothelial and Progenitor Cells in Heart Failure. Journal of Cardiovascular Development and Disease, 2022, 9, 222.	1.6	8
44	Impact analysis of heart failure across European countries: an ESCâ€HFA position paper. ESC Heart Failure, 2022, 9, 2767-2778.	3.1	17
45	Matrix Metalloproteinase 2 as a Pharmacological Target in Heart Failure. Pharmaceuticals, 2022, 15, 920.	3.8	20
46	Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	2
47	Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care. Expert Opinion on Pharmacotherapy, 2022, 23, 1589-1599.	1.8	5
48	Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials. ESC Heart Failure, 2022, 9, 3737-3750.	3.1	12
49	Risk stratification models for predicting mortality in heart failure: a favourite or an outsider?. European Journal of Preventive Cardiology, 2024, 31, 272-273.	1.8	0
50	Microbial metabolites and heart failure: Friends or enemies?. Frontiers in Microbiology, 0, 13, .	3.5	3
52	Differences in the prognostic value of the electrocardiographic pattern after cardiac resynchronization therapy according to age. Archives of Gerontology and Geriatrics, 2022, , 104826.	3.0	0
53	U-Shaped Relationship of Sodium-to-chloride RatioÂon admission and Mortality in Elderly Patients with Heart Failure. Current Problems in Cardiology, 2022, 48, 101419.	2.4	4
54	Heart Failure Association/European Society of Cardiology Atlas second edition: new insights into understanding the burden of heart failure. European Heart Journal, 0, , .	2.2	0
55	The strategic vision of the 2022–2024 mandate–Âgreater involvement of members, young specialists for an <scp>HFA</scp> community without borders. European Journal of Heart Failure, 2022, 24, 1458-1459.	7.1	1
56	How the on-going conflict in Ukraine is impacting cardiovascular health. European Heart Journal, 0, , .	2.2	Ο

#	Article	IF	CITATIONS
57	Association between heart failure quality of care and mortality: a populationâ€based cohort study using nationwide registries. European Journal of Heart Failure, 2022, 24, 2066-2077.	7.1	8
58	Clinical inertia in heart failure care – Should we worry? Insights from "real-world―practice. Revista Portuguesa De Cardiologia, 2022, , .	0.5	0
59	Low blood pressure and guideline-directed medical therapy in patients with heart failure with reduced ejection fraction. International Journal of Cardiology, 2023, 370, 255-262.	1.7	3
60	Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond – major changes are coming. Journal of Cardiovascular Medicine, 2022, 23, 761-769.	1.5	4
61	Introduction of specialized heart failure nurses in primary care and its impact on readmissions. Primary Health Care Research and Development, 2022, 23, .	1.2	0
62	«BRIDGE» TO HEART TRANSPLANTATION: HEMOSORPTION, VENTRICULAR REMODELING OR LVAD? ABSTRACT. Pain Anesthesia and Intensive Care, 2022, , 7-14.	0.1	Ο
65	Heart failure: an update from the last years and a look at the near future. ESC Heart Failure, 2022, 9, 3667-3693.	3.1	24
66	Effect of arotinolol on chronic heart failure: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	Ο
67	Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study). Journal of Clinical Medicine, 2023, 12, 699.	2.4	4
68	Potential Mechanisms Between HF and COPD: New Insights From Bioinformatics. Current Problems in Cardiology, 2023, 48, 101539.	2.4	2
69	Motivational Interviewing for Enhancing Self-care in Patients With Heart Failure: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 0, 12, e44629.	1.0	1
70	Management of Heart Failure With Reduced Ejection Fraction. Current Problems in Cardiology, 2023, 48, 101596.	2.4	5
71	Efficacy of peritoneal dialysis in patients with refractory congestive heart failure: a systematic review and meta-analysis. Heart Failure Reviews, 2023, 28, 1053-1063.	3.9	2
72	Bone status in men with heart failure: results from the Studies Investigating Coâ€morbidities Aggravating Heart Failure. European Journal of Heart Failure, 0, , .	7.1	3
73	Prevalence, outcomes and costs of a contemporary, multinational population with heart failure. Heart, 0, , heartjnl-2022-321702.	2.9	3
74	Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat. Patient Preference and Adherence, 0, Volume 17, 839-849.	1.8	0
75	Treatment Strategies of Improving Quality of Care in Patients With Heart Failure. Korean Circulation Journal, 2023, 53, 294.	1.9	4
76	The Heart Failure Association endorses theÂ25in25 initiative. European Journal of Heart Failure, 2023, 25, 602-603.	7.1	0

#	Article	IF	Citations
79	Cardiovascular Biomarkers in Acute Myocardial Infarction. , 2023, , 139-169.		0
80	Optimizing outcomes in heart failure: 2022 and beyond. ESC Heart Failure, 2023, 10, 2159-2169.	3.1	3
81	Remote multiparametric monitoring and management of heart failure patients through cardiac implantable electronic devices. European Journal of Internal Medicine, 2023, 115, 1-9.	2.2	8
82	The Present Clinical Treatment and Future Emerging Interdisciplinary for Heart Failure: Where we are and What we can do. Intensive Care Research, 2023, 3, 3-11.	0.6	3
83	Factores asociados a mortalidad intrahospitalaria en falla cardiaca aguda. Revista Investigación En Salud Universidad De Boyacá, 2022, 9, .	0.1	0
84	Results of an observational retrospective multicenter study: "Campania INternal medicine - the Clinical INternist for heart failure― Italian Journal of Medicine, 2023, 17, .	0.3	0
85	Cellular and molecular biology of sirtuins in cardiovascular disease. Biomedicine and Pharmacotherapy, 2023, 164, 114931.	5.6	4
86	Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2023, 25, 776-791.	7.1	33
87	History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case–control study. BMJ Open, 2023, 13, e069037.	1.9	0
88	Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes. Heart, 2023, 109, 1159-1165.	2.9	10
89	Preâ€discharge and early postâ€discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC. European Journal of Heart Failure, 2023, 25, 1115-1131.	7.1	16
90	An update on utilising brain natriuretic peptide for risk stratification, monitoring and guiding therapy in heart failure. Expert Review of Molecular Diagnostics, 2023, 23, 521-533.	3.1	1
91	Unlocking the potential of natriuretic peptide testing in primary care: A roadmap for early heart failure diagnosis. European Journal of Heart Failure, 2023, 25, 1181-1184.	7.1	1
92	Analysis of the information about the incidence of heart failure, associated mortality and burden on the healthcare system, based on the encoding data in 15 subjects of the Russian Federation. Russian Journal of Cardiology, 2023, 28, 5339.	1.4	1
93	Effect of axial flow blood pump's pulsation speed regulation on key hemodynamic parameters. Journal of Mechanics in Medicine and Biology, 0, , .	0.7	0
94	Culture, ethnicity, and socioâ€economic status as determinants of the management of patients with advanced heart failure who need palliative care: A clinical consensus statement from the Heart Failure Association (<scp>HFA</scp>) of the <scp>ESC</scp> , the <scp>ESC</scp> Patient Forum, and the European Association of Palliative Care. European Iournal of Heart Failure. 2023. 25. 1481-1492.	7.1	3
95	Palliative care in heart failure guidelines: A comparison of the 2021 <scp>ESC</scp> and the 2022 <scp>AHA</scp> / <scp>ACC</scp> / <scp>HFSA</scp> guidelines on heart failure. European Journal of Heart Failure, 2023, 25, 1849-1855.	7.1	5
96	Dapagliflozin-affected endothelial dysfunction and altered gut microbiota in mice with heart failure. PeerJ, 0, 11, e15589.	2.0	4

#	Article	IF	CITATIONS
97	Heart Failure Prevalence Rates and Its Association with Other Cardiovascular Diseases and Chronic Kidney Disease: SIMETAP-HF Study. Journal of Clinical Medicine, 2023, 12, 4924.	2.4	0
98	Trends in heart failure between 2016 and 2022 in Türkiye (TRends-HF): a nationwide retrospective cohort study of 85 million individuals across entire population of all ages. Lancet Regional Health - Europe, The, 2023, 33, 100723.	5.6	1
99	Recent Advances in Microbiota-Associated Metabolites in Heart Failure. Biomedicines, 2023, 11, 2313.	3.2	5
100	Glial Activation, Mitochondrial Imbalance, and Akt/mTOR Signaling May Be Potential Mechanisms of Cognitive Impairment in Heart Failure Mice. Neurotoxicity Research, 2023, 41, 589-603.	2.7	1
101	Associations between systemic immunity-inflammation index and heart failure: Evidence from the NHANES 1999–2018. International Journal of Cardiology, 2024, 395, 131400.	1.7	4
102	Advances in the design, generation, and application of tissue-engineered myocardial equivalents. Frontiers in Bioengineering and Biotechnology, 0, 11, .	4.1	0
103	Gut Microbiota and Derived Short-Chain Fatty Acids Are Linked to Evolution of Heart Failure Patients. International Journal of Molecular Sciences, 2023, 24, 13892.	4.1	2
104	In Search of the Holy Grail of Artificial Hearts: Are We There Yet?. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	0
105	Predictors and prognostic implications of hospital-acquired pneumonia in patients admitted for acute heart failure. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
106	Practical algorithms for early diagnosis of heart failure and heart stress using <scp>NTâ€proBNP</scp> : A clinical consensus statement from the Heart Failure Association of the <scp>ESC</scp> . European Journal of Heart Failure, 2023, 25, 1891-1898.	7.1	13
107	Epigenetic signals in heart failure: new opportunities for early diagnosis and eff ective therapy. Klinicheskaia Meditsina, 2023, 101, 353-360.	0.1	0
108	Targeting mitochondrial shape: at the heart of cardioprotection. Basic Research in Cardiology, 2023, 118, .	5.9	3
109	Portuguese Heart Failure Prevalence Observational Study (PORTHOS) rationale and design – A population-based study. Revista Portuguesa De Cardiologia, 2023, 42, 985-995.	0.5	0
110	Rationale and design of the <scp>ESC</scp> Heart Failure <scp>III</scp> Registry–ÂImplementation and discovery. European Journal of Heart Failure, 2023, 25, 2316-2330.	7.1	2
111	Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban. Clinical Cardiology, 2024, 47, .	1.8	0
112	Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF. ESC Heart Failure, 0, , .	3.1	0
113	European Society of Cardiology guidelines and 1Âyear outcomes of acute heart failure treatment in Central Asia and Europe. ESC Heart Failure, 0, , .	3.1	0
114	The â€~peptide for life' initiative in the emergency department study. ESC Heart Failure, 0, , .	3.1	0

#	Article	IF	CITATIONS
115	Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction. Cardiac Failure Review, 0, 9, .	3.0	0
116	Obesity, heart failure with preserved ejection fraction, and the role of glucagonâ€like peptideâ€1 receptor agonists. ESC Heart Failure, 0, , .	3.1	0
117	A highly accurate prediction for heart failure disease: a new deep attentive model with guided feature ranking. Arabian Journal for Science and Engineering, 0, , .	3.0	0
118	Left ventricular assist device and transcatheter edge-to-edge mitral valve repair in advanced heart failure: allies or enemies?. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
119	Association between performance measures and clinical outcomes in patients with heart failure in China: Results from the HERO study. Clinical Cardiology, 2024, 47, .	1.8	0
120	Heart Failure Prediction for a Patient Using Hybrid African Buffalo Optimization with Naive Bayes Machine Learning Techniques. Smart Innovation, Systems and Technologies, 2024, , 141-154.	0.6	0
121	An Update on the Prevalence of Heart Failure. Updates in Hypertension and Cardiovascular Protection, 2023, , 13-26.	0.1	0
122	Cardiac Biomarkers in the Progression to Heart Failure in Hypertension. Updates in Hypertension and Cardiovascular Protection, 2023, , 277-297.	0.1	0
123	Healthcare needs in elderly patients with chronic heart failure in view of a personalized blended collaborative care intervention: a cross sectional study. Frontiers in Cardiovascular Medicine, 0, 11, .	2.4	0
124	Novel Strategies in Diagnosing Heart Failure with Preserved Ejection Fraction: A Comprehensive Literature Review. High Blood Pressure and Cardiovascular Prevention, 2024, 31, 127-140.	2.2	0
125	Obesity: the perfect storm for heart failure. ESC Heart Failure, 0, , .	3.1	0
126	Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement. ESC Heart Failure, 0, , .	3.1	0
127	Burden of heart failure in Asia, 1990–2019: findings from the Global Burden of Disease Study 2019. Public Health, 2024, 230, 66-72.	2.9	0
128	The multidimensional value of natriuretic peptides in heart failure, integrating laboratory and clinical aspects. Critical Reviews in Clinical Laboratory Sciences, 0, , 1-15.	6.1	0
129	The Importance of Cultural Awareness in the Management of Heart Failure: A Narrative Review. Vascular Health and Risk Management, 0, Volume 20, 109-123.	2.3	0
130	Extrahepatic Vitamin K-Dependent Gla-Proteins–Potential Cardiometabolic Biomarkers. International Journal of Molecular Sciences, 2024, 25, 3517.	4.1	0